Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

A series of disappointing trial results for Novo Nordisk’s next-generation weight-loss drugs has exacerbated investor ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...